Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellular Origins, J&J Partner for CGT Robotics Manufacturing Platform | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Cellular Origins, J&J Partner for CGT Robotics Manufacturing Platform

Aim to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing using Cellular Origins’ automated robotics platform.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Cellular Origins has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing.

Cellular Origins has successfully shown that its platform is able to fully automate cell therapy manufacturing processes using validated, off-the-shelf third-party instruments in combination with mobile robots and Cellular Origins’ proprietary sterile fluid transfer technology. As a next step, Cellular Origins is developing its first end-to-end, GMP-ready system for clinical manufacturing.

This news comes after J&J recently shared promising cell therapy clinical data. They announced the first data from a Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy. JNJ-4496 showed potential in treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who haven’t been previously treated with CAR T-cell therapy. It also showed promise in treating R/R diffuse large B-cell lymphoma (DLBCL), the most common type of aggressive lymphoma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics